Verisk ($VRSK) Reports Q3 Earnings & Updates Full-Year Guidance
Verisk Analytics, Inc.
Subscribe to track VRSK
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Verisk ($VRSK) Reports Q3 Earnings & Updates Full-Year Guidance
Company: Verisk Analytics, Inc. (VRSK) Form: 8-K | Filed: 2025-10-29 Significance: High
Event: Q3 2025 Earnings Release
Key Financials: • Revenue: $768M (+5.9% YoY) • Diluted EPS: $1.61 (+4.5% YoY) • Adj. EBITDA: $429M (+7.2% YoY)
Key Insight: Verisk reported solid Q3 results but updated its full-year 2025 revenue and Adjusted EBITDA guidance to a slightly lower range. The company also disclosed that its pending acquisition of AccuLynx is under a 'Second Request' review by the FTC, indicating deeper antitrust scrutiny.
Corporate Actions: • Repurchased $100M of stock (0.4M shares) in Q3. • Approved a quarterly dividend of $0.45 per share.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Verisk Analytics, Inc. (VRSK)
Executive Summary
- Trading Significance: High
- Key Takeaway: Verisk Analytics filed an 8-K to announce its Q3 2025 financial results, which showed steady growth but was accompanied by a downward revision of its full-year guidance and news of an extended FTC review for a pending acquisition.
- Market Impact: The combination of revised guidance and regulatory scrutiny on a strategic acquisition could introduce negative pressure and uncertainty for the stock, despite solid quarterly performance.
Company Information
| Field | Value |
|---|---|
| Company | Verisk Analytics, Inc. |
| Ticker Symbol | VRSK |
| CIK | 0001442145 |
| Industry | SERVICES-COMPUTER PROCESSING & DATA PREPARATION |
Insider Information
| Field | Value |
|---|---|
| Name | null |
| CIK | null |
| Title/Position | null |
| Relationship | null |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 8-K |
| Transaction Date | 2025-10-29 |
| Transaction Code | null |
| Security Type | null |
| Shares Involved | null |
| Price Per Share | null |
| Total Value | null |
| Shares Owned After | null |
| Ownership Type | null |
Financial Impact Assessment
This filing reports corporate events, not an insider transaction. The most relevant financial action is the company's share repurchase program.
Corporate Action Materiality (Share Repurchase)
| Metric | Value |
|---|---|
| Transaction Value | $100,000,000 |
| % of Market Cap | 0.30% |
| Shares Transacted | 400,000 |
| % of Shares Outstanding | 0.29% |
| Remaining Authorization | $1.2 billion |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: For a company with a market cap of $32.82 billion, the $100 million share repurchase in Q3 is a routine capital return activity and is not financially material on its own. It represents just 0.30% of the company's market value.
- Earnings and Guidance: The key event is the earnings release. While Q3 results were strong (e.g., 5.9% revenue growth), the updated full-year 2025 guidance reflects a slight reduction in expectations for both revenue and adjusted EBITDA. This revision, even if minor, can be interpreted negatively by the market.
- Regulatory Scrutiny: The disclosure of a 'Second Request' from the FTC regarding the AccuLynx acquisition is a significant development. It signals a more in-depth antitrust investigation, creating uncertainty about the deal's closure, timing, and potential required concessions. This introduces a new risk factor for investors.
Market Impact Analysis
Stock Impact Prediction
- Direction: Negative to Neutral
- Reasoning: While the Q3 earnings were solid, the market often reacts more strongly to forward-looking statements. The lowered guidance and the FTC investigation news are likely to overshadow the positive quarterly results, potentially leading to a neutral or negative stock reaction as investors price in the new uncertainty.
Volume & Sentiment
- Expected Volume Impact: High. Earnings reports, guidance updates, and news of regulatory hurdles are significant catalysts that typically drive above-average trading volume.
- Sentiment Indicator: Bearish. The combination of lowered guidance and regulatory risk is a bearish signal, suggesting potential headwinds for the company's growth strategy.
Investment Insights
Positive Market Indicators
- Consistent revenue and adjusted EBITDA growth in Q3.
- Strong free cash flow growth of 39.6% in the quarter.
- Continued capital return to shareholders via dividends and buybacks.
Risk Factors
- Full-year 2025 guidance was revised downwards.
- The pending AccuLynx acquisition faces significant regulatory delay and potential risk of being blocked by the FTC.
- CFO Elizabeth Mann noted that a historically low level of severe weather events negatively impacted growth by approximately 1%, indicating some revenue sensitivity to external factors.
Key Takeaways
- Guidance Over Earnings: The market is likely to focus more on the lowered full-year outlook than the solid Q3 performance.
- Regulatory Headwind: The FTC's 'Second Request' for the AccuLynx deal is a material event, creating significant uncertainty around a key part of Verisk's growth plan.
- Capital Returns Continue: Despite headwinds, the company remains committed to returning capital to shareholders through its ongoing dividend and a $1.2 billion remaining share repurchase authorization.
Additional Context
Transaction Notes
- Event: This 8-K filing serves as the official announcement of Verisk's financial results for the third quarter ended September 30, 2025.
- Timing: The filing was made on the morning of October 29, 2025, ahead of a scheduled conference call with management to discuss the results.
- Market Environment: The report comes at a time when investors are highly sensitive to corporate guidance and execution on strategic initiatives like M&A.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
